News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agensys, Inc. And Sea Lane Biotechnologies, LLC Sign Commercial License Agreement For Antibodies Generated Using ConCIRT Libraries



6/2/2014 2:58:52 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Santa Monica and Mountain View, CA, U.S.A., JUNE 2, 2014 - Agensys, Inc. (“Agensys”), a wholly owned subsidiary of Astellas Pharma Inc. (“Astellas”), and Sea Lane Biotechnologies (“Sea Lane”) jointly announced today that Agensys has taken a commercial license to antibodies generated using Sea Lane’s ConCIRT libraries and related technology. Located in the Silicon Valley, Sea Lane is a biotech company with technologies and inventions that include the therapeutic class of entities known as Surrobodies™ and human antibody libraries.

“We are excited by the potential of these unique antibodies to help treat disease,” said David Stover, Ph.D., Executive V.P., Site Head at Agensys.

Under the terms of the agreement, Sea Lane grants Agensys a license to commercialize antibodies generated using its patented ConCIRT libraries, and Agensys will be responsible for preclinical research, clinical development, and marketing of the licensed biotherapeutic products.

"We are very pleased to enter into this agreement with Agensys," commented Lawrence Horowitz, M.D., Chief Executive Officer of Sea Lane. "The progression of our relationship with Agensys shows the potential for innovative technologies such as our ConCIRT libraries and related technologies to facilitate discovery and development of biotherapeutics for large pharmaceutical companies."

About Sea Lane Biotechnologies, LLC
Sea Lane Biotechnologies, LLC is a private biotechnology company focused on innovating biotherapeutic discovery with transformative technologies and platforms that are necessary to meet contemporary pharmaceutical biologic portfolio requirements, including bispecific and drug conjugated agents. Founded in 2005 in the Silicon Valley, the company is dedicated to the discovery and development of biotherapeutic drugs based upon a novel class of proteins called Surrobodies™ and the discovery of world-class antibodies for the treatment of serious human diseases, such as cancer and viral infection. Sea Lane currently has several proprietary product candidates in preclinical development.

About Agensys, Inc.
Agensys, Inc., an affiliate of Astellas Pharma Inc., is developing a pipeline of fully human monoclonal antibodies (MAbs) to treat cancer. The MAb product pipeline is being generated to Agensys’ diverse portfolio of proprietary, clinically relevant cancer targets. The company has full capabilities to generate, develop and manufacture antibody products. Agensys is progressing a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies.

Contacts:
Astellas
Jenny M. Kite
224-205-5405
jenny.kite@astellas.com

Sea Lane Biotechnologies, LLC
Michael Horowitz
650-336-1532
Michael.horowitz@sealanebio.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES